Dx & Vx Co., Ltd.

A180400

KR7180400004

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
4,490 ^KRW	-0.44%		-2.81%	-24.03%

2023	Dx&Vx Co-Develops Bio-Healthcare Big Data Platform with LG CNS	CI
2023	Dx & Vx Co., Ltd. completed the acquisition of Avixgen, Inc. from a group of sellers	CI

Cancer Rop Co., Ltd. announced that it has received KRW 10 billion in funding

April 12, 2018

On April 13, 2018, Cancer Rop Co., Ltd. (KOSDAQ:A180400) closed the transaction. The company received proceeds of KRW 10,000,000,000.

Latest news about Dx & Vx Co., Ltd.

Dx&Vx Co-Develops Bio-Healthcare Big Data Platform with LG CNS	Dec. 20	CI
Dx & Vx Co., Ltd. completed the acquisition of Avixgen, Inc. from a group of sellers	23-06-27	CI
Dx & Vx Co., Ltd. announced that it has received KRW 9.223311402 billion in funding from Renaissance Asset Management and other investors	23-06-13	CI
Dx & Vx Co., Ltd. agreed to acquire Avixgen, Inc. from Renaissance Asset Management, Nouveau International Co., Ltd., Lee Mi-ja, Seo Jin - young, Kim Jae-hyun , Cho Il-hyun,Park So -yeon, Jeong Ja -woon, Kim Young- ju, Yang Young-jin, Kim Hye -min and Um In-kyung for KRW 9.2 billion.	23-05-23	CI
DxVx Appoints Kevin Kwon as New President	23-05-16	CI
DxVx Appoints Yong Gu Lee as CEO	23-05-16	CI
Dx & Vx Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-13	CI
Dx & Vx Co., Ltd. announced that it expects to receive KRW 9.223311402 billion in funding from Renaissance Asset Management and other investors.	23-04-06	CI
Dx & Vx Co., Ltd. announced that it has received KRW 17 billion in funding	22-10-05	CI
Dx & Vx Co., Ltd. completed the acquisition of Korea Biopharm Co., Ltd. from Jang, Byung Ha, Heo, Won Jung, Kim, Min E, Jang, So Yeon, Kim, Sung Gon and Hyun, Mi Ok.	22-10-03	CI
Dx & Vx Co., Ltd. agreed to acquire Korea Biopharm Co., Ltd. from Jang, Byung Ha, Heo, Won Jung, Kim, Min E, Jang, So Yeon, Kim, Sung Gon and Hyun, Mi Ok for approximately KRW 15 billion.	22-09-14	CI
Dx & Vx Co., Ltd. announced that it expects to receive KRW 1.78 billion in funding	22-09-06	CI
Cancer Rop Co., Ltd. announced that it expects to receive KRW 20 billion in funding	21-08-29	CI
Cancer Rop Co., Ltd. announced that it has received KRW 999.99252 million in funding	20-06-28	CI
Cancer Rop Co., Ltd. announced that it expects to receive KRW 999.99252 million in funding	20-06-17	CI
D S and partners limited company cancelled the acquisition of 10.2% stake in GI Innovation, Inc. from Cancer Rop Co., Ltd..	20-04-28	CI
Cancer Rop Holdings Co., Ltd. cancelled the acquisition of 3.4% stake in Cancer Rop Co., Ltd. from Myungji Global Bio Fund.	19-07-10	CI
Ds&Partners signed a contract to acquire 10.2% stake in GI Innovation, Inc. from Cancer Rop Co., Ltd. for KRW 7.5 billion.	19-04-28	CI
Resort Savers, Inc. Announces Medical Distribution Partnership with South Korea based CancerROP	18-07-16	CI
GI Innovation, Inc. announced that it has received KRW 4.999995 billion in funding from Cancer Rop Co., Ltd.	18-07-12	CI
Cancer Rop Holdings Co., Ltd. singed a contract to acquire 3.4% stake in Cancer Rop Co., Ltd. from Myungji Global Bio Fund for approximately KRW 9.5 billion.	18-07-10	CI
GI Innovation, Inc. announced that it expects to receive KRW 4.999995 billion in funding from Dx & Vx Co., Ltd.	18-06-27	CI
Cancer Rop Co., Ltd. announced that it has received KRW 10 billion in funding	18-04-12	CI
Oxford Vacmedix UK Limited announced that it has received KRW 13.28575 billion in funding from Cancer Rop Co., Ltd.	18-03-05	CI
Oxford Vacmedix UK Limited announced that it expects to receive KRW 10.618366 billion in funding from Cancer Rop Co., Ltd.	18-03-04	CI

Dx & Vx Co Ltd, formerly Cancer Rop Co Ltd, is a Korea-based company primarily engaged in the molecular diagnosis business. The Molecular Diagnosis Business segment is engaged in the manufacture and sale of deoxyribonucleic acid (DNA) chips, polymerase chain reaction (PCR) chips and other products. manufacture and sale of diagnostic reagents used for molecular diagnosis, and various enzymes and experimental reagents used for biological research.

Sector

Biotechnology & Medical Research

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
DX & VX CO., LTD.	-24.03%	99.44M
EXACT SCIENCES CORPORATION	-27.41%	9.96B
GUARDANT HEALTH, INC.	-7.45%	3.03B
IOVANCE BIOTHERAPEUTICS, INC.	+31.73%	3B
BGI GENOMICS CO., LTD.	-14.73%	2.18B
VERACYTE, INC.	-14.50%	1.76B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+66.95%	1.42B
CAREDX, INC	+23.42%	794M
SEEGENE, INC.	-2.18%	756M
CURIOX BIOSYSTEMS CO., LTD	+3.18%	305M

Bio Diagnostics & Testing

Dx & Vx Co., Ltd.

Equities

A180400

KR7180400004

Biotechnology & Medical Research

Cancer Rop Co., Ltd. announced that it has received KRW 10 billion in funding

Latest news about Dx & Vx Co., Ltd.

Chart Dx & Vx Co., Ltd.

Company Profile

Income Statement Evolution

Sector Bio Diagnostics & Testing